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Although lithium has been used in the treatment of vari-
ous psychiatric conditions in the past 4 decades, it is par-
ticularly beneficial for the acute and long-term treatment
of mania and in some bipolar and unipolar patients, for
prophylaxis and treatment of depression. In recent years,
however, young physicians have largely ignored the bene-
fits of lithium in favor of anticonvulsant or atypical antip-
sychotic pharmacotherapy for patients with bipolar
disorder. Moreover, while lithium was studied extensively
in the past, recent literature shows a paucity of controlled
studies of the drug. The effects of lithium on depolariza-
tion-provoked and calcium-dependent release of
dopamine and norepinephrine from nerve terminals in
the central nervous system (CNS), neuronal second mes-
senger signaling pathways, CNS cytoprotective proteins,
and the distribution of Na+, Ca+ and Mg+ across neuronal
membranes all have been suggested to contribute to its
therapeutic effects. Adverse events occur in 35% to 93% of
lithium-treated patients. Most of the common side effects,
which include excessive thirst, polyuria, memory prob-
lems, tremor, weight gain, drowsiness and diarrhea, are
troublesome rather than life-threatening, but some, such
as memory problems, tremor and weight gain, often lead
to noncompliance. More recent studies have found that
42% to 64% of patients with bipolar disorder do not
respond to lithium treatment, including patients with
mixed states, personality disorders, comorbid substance
abuse, mania secondary to other medical conditions,
rapid cycling, or previous failed trials of lithium. The
effectiveness of lithium prophylaxis appears to be dose
dependent. It has been reported that a lithium dose that
was adjusted to maintain a target serum concentration of
0.8 to 1.0 mmol/L was more effective at preventing
relapse than a lower dose targeted to maintain a serum
lithium concerntration of 0.4 to 0.6 mmol/L. However,
the higher dose was associated with an increased inci-
dence of side effects. Finally, many patients discontinue
their lithium use after a relatively short period of time. In
an analysis of data from a large health maintenance
organization, half of patients prescribed lithium discon-
tinued it within about 10 weeks, and this discontinuation
was associated with an increased likelihood of psychiatric
hospitalization. It has also been show that, occasionally
patients stabilized on lithium of extended periods of time
may become lithium-resistant after discontinuing the
agent and then suffer a relapse.
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